RENXF — Renalytix plc

OTC · Health Care · Health Care Providers & Services · CIK 1811115 · United Kingdom
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 9,900,000 6,100,000 11,100,000
Dec 2024 729,000 398,000 -3,396,000 -3,882,000 11,441,000 9,209,000 12,810,000
Sep 2024 522,000 100,000 -4,092,000 -4,728,000 4,794,000 909,000 16,113,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,333,000
Investing CF
$22,000
Financing CF
$15,035,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-173,400,000
Inventory
$300,000
Receivables
ST Investments
$100,000
EBIT TTM
$-8,510,000
Pretax Income TTM
$-8,610,000
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,300,000
EBITDA
Free Cash Flow
Enterprise Value
$9,695,132
Total Cash
$6,200,000
Total Debt
$5,800,000
Shares Out
437,018,680
Trailing EPS
$-0.04
Book Value
$-0.00
ROE
ROA
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 3,000,000 -17,200,000 -20,400,000 6,100,000 13,100,000 -17,900,000
Jun 2024 2,300,000 -30,500,000 -45,500,000 7,100,000 16,100,000 -29,800,000
Jun 2023 3,403,000 -42,221,000 -45,607,000 30,629,000 23,662,000 -34,085,000
Jun 2022 2,970,000 -53,183,000 -45,276,000 50,065,000 19,458,000 -45,924,000

Peers — same industry

TickerNameMarket CapLastDaily %
HCA HCA Healthcare, Inc. $87.05B $392.42
NTRA Natera, Inc. $28.77B $200.91
DGX QUEST DIAGNOSTICS INC $21.35B $192.88
LH LABCORP HOLDINGS INC. $21.19B $258.45
GH Guardant Health, Inc. $15.89B $119.85

News headlines (Yahoo Finance, 1h cache)

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
2026-05-12 11:43 · Yahoo
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
2025-09-15 12:00 · Yahoo
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
2025-07-21 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.